| Date | Title | Description | Source |
| 23.04.2024 | New report presents good figures from the Swiss biotech sect... |
The overall picture of the Swiss biotech industry in the Swiss Biotech Report published today is qu... | startuptic... |
| 02.04.2024 | A positive growth trajectory for three pharmaceutical startu... | Based in Basel, Santhera has pipeline of drugs for neuromuscular and pulmonary diseases that current... | startuptic... |
| 22.03.2024 | FDA Nod in Duchenne Helps Wider Swath of Patients With the R... | Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides child... | medcitynew... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE... | AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne m... | einpresswi... |
| 14.03.2024 | Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE... | - | globenewsw... |
| 13.10.2023 | EU approval for Santhera's vamorolone in sight | | startuptic... |
| 07.08.2023 | Chiesi Group acquires Santhera’s idebenone assets | | startuptic... |
| 20.06.2023 | Santhera Grants Exclusive North America License for Vamorolo... | - | globenewsw... |
| 20.06.2023 | Fresh money for Santhera and Idorsia | | startuptic... |
| 16.01.2023 | Listed Swiss Biotechs at full throttle | | startuptic... |
| 28.10.2022 | Penny stock forges ahead with an NDA for Duchenne treatmen... | After setbacks and delays, the Swiss biotech Santhera is looking to have its treatment for Duc... | endpts.com... |
| 01.03.2022 | New start-up takes over gene therapy approach for a rare dis... | | startuptic... |
| 04.01.2022 | Santhera inks exclusive agreement with USD 20M upfront payme... | | startuptic... |
| 20.09.2021 | Santhera Secures CHF 45 Million in Funding and Announces Pre... | (MORE TO FOLLOW) Dow Jones Newswires
September 20, 2021 01:00 ET (05:00 GMT) | marketscre... |
| 20.09.2021 | Santhera Secures CHF 45 Million | | startuptic... |
| 22.06.2021 | Press Release : Santhera's Shareholders Approve all Board Pr... | Pratteln, Switzerland, June 22, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces that its shar... | marketscre... |
| 27.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | Pratteln, Switzerland, May 27, 2021 -- Santhera Pharmaceuticals (SIX: SANN) announces the invitation... | marketscre... |
| 07.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO... | marketscre... |
| 04.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Santhera Pharmaceutical... | Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24, 4133 Pratteln, Schweiz
Tel.: +41 61 906 89 ... | marketscre... |
| 04.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO... | marketscre... |
| 03.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO... | marketscre... |
| 03.05.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Santhera Pharmaceutical... | Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24, 4133 Pratteln, Schweiz
Tel.: +41 61 906 89 ... | marketscre... |
| 27.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | persons within the United Kingdom falling within the definition of investment professionals (as defi... | marketscre... |
| 27.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO... | marketscre... |
| 20.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | its officers or directors in a Swiss court or another court outside the United States for violations... | marketscre... |
| 20.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO... | marketscre... |
| 06.04.2021 | SANTHERA PHARMACEUTICALS HOLDING AG
Press Release : Santher... | comparable to the financial statements or financial information of United States companies. It may b... | marketscre... |
| 27.08.2019 | Santhera's Duchenne effort gets a boost on positive PhI... | Months after Santhera got its hands on a second Duchenne muscular dystrophy drug, the Swiss ... | endpts.com... |
| 15.02.2018 | Santhera licenses drug from Polyphor | | startuptic... |
| 11.12.2015 | Grundstein für neues Spin-off am Biozentrum Basel gelegt | | startuptic... |
| 09.09.2015 | Market approval for Santhera’s Raxone | | startuptic... |
| 07.08.2015 | Santhera raises CHF 27.7 million in new capital | | startuptic... |
| 17.04.2015 | Nine hot start-ups, 400 visitors and Joe Jimenez | | startuptic... |
| 03.09.2010 | Santhera and Ipsen enter into licensing agreement for Fipame... | Santhera Pharmaceuticals (SIX: SANN) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced a license... | neomed.net... |
| 06.11.2008 | Santhera raises CHF 15.9 million in private placement with s... | Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscu... | neomed.net... |
| 05.10.2006 | Santhera raises up to EUR 15 million in oversubscribed Serie... | Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company with a focus on neuromuscular dis... | neomed.net... |
